Costs of Invasive Meningococcal Disease: A Global Systematic Review

Wang, Bing; Santoreneos, Renee; Afzali, Hossein Haji Ali; Giles, Lynne C.; Marshall, Helen

doi:10.1007/s40273-018-0679-5

Cited by 24 publications

(15 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The case fatality rate of IMD is high with 5-15% and up to 57% of survivors in adolescents aged 15 to 19 years develop a wide range of sequelae [7][8][9][10][11] such as hearing loss, visual impairment, neurological impairments or limb amputation. As a result, IMD is associated with substantial short-term and long-term costs for health care systems [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database

et al. 2020

View full text Add to dashboard Cite

Background Limited data is available to describe clinical characteristics, long-term outcomes, healthcare resource use and the attributable costs of invasive meningococcal disease (IMD) in Germany. We aimed to examine demographic and clinical characteristics as well as healthcare resource use and related costs. Methods We conducted a retrospective cohort study based on the InGef database in patients with IMD between 2009 and 2015. Cases were identified based on hospital main discharge diagnoses of IMD. Demographics, clinical characteristics, 30-day and 1-year mortality as well as IMD-related complications and sequelae in IMD cases were examined. In addition, short and long-term costs and healthcare resource use in IMD cases were analyzed and compared to an age-and sex-matched control group without IMD. Results The study population comprised 164 IMD cases between 2009 and 2015. The mean length of the IMD-related hospitalization was 13 days and 38% of all cases presented with meningitis only, 35% with sepsis only, 16% with both and 11% with other IMD. The 30-day and oneyear mortality were 4.3% and 5.5%, respectively. Approximately 13% of IMD cases had documented IMD-related complications at hospital discharge and 24% suffered from sequelae during follow-up. The IMD-related hospitalization was associated with mean costs of € 9,620 (standard deviation: € 22,197). The difference of mean costs between IMD cases and matched non-IMD controls were € 267 in the first month and € 1,161 from one month to one year after discharged from IMD-related hospitalization. During the later follow-up period, the mean overall costs and costs associated with individual healthcare sectors were also higher for IMD cases without reaching statistical significance.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A systematic review has already been conducted to evaluate the clinical and financial burden of IMD. 4 , 30 In addition, a comprehensive systematic review of the extant literature will be performed to assess the burden of gonorrhoea. This review will be used to identify the best model for cost effectiveness analysis.…”

Section: Methods and Analysesmentioning

confidence: 99%

Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol

Marshall

Wang

McMillan

et al. 2021

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Invasive meningococcal disease causes significant morbidity and mortality worldwide, with serogroup B being one of the predominant serogroups in Australia for many years. The South Australian (SA) State Government recently funded the introduction of a 4CMenB vaccination program for infants, children and adolescents. In addition to protecting against invasive meningococcal disease, emerging evidence suggests the 4CMenB vaccine may also be effective against gonorrhoea due to genetic similarities between Neisseria meningitidis and Neisseria gonorrhoeae . The proposed project aims to evaluate the effectiveness of the SA 4CMenB vaccination program against invasive meningococcal disease and gonorrhoea through a combination of observational studies using routine surveillance and research data. The main methodological approaches involve an interrupted time series regression model, screening, and case-control analyses with different sets of controls to estimate vaccine impact and effectiveness. These analyses are designed to minimize potential biases inherent in all observational studies and to provide critical data on the effectiveness of the 4CMenB vaccine against two diseases of major global public health concern.

show abstract

“…Cost of illness studies of IMD are scarce and, for this reason, the economic burden of IMD is poorly characterised [ 13 ]. A major reason for this is that IMD is an uncommon disease with a heterogenous prognosis, and so it is challenging to assemble large representative patient cohorts that enable these costs to be determined with precision.…”

Section: Introductionmentioning

confidence: 99%

Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database

et al. 2021

View full text Add to dashboard Cite

Introduction: Invasive meningococcal disease (IMD) is an uncommon but serious infectious disease. Its economic burden is known to be high but is poorly characterised. The objective of this study was to determine costs, as captured in the healthcare claims database, incurred by all patients hospitalised for IMD in France over a 6-year period. Methods: This case-control study was performed using the French national public health insurance database (SNDS). Cases comprised all individuals hospitalised with acute IMD in

show abstract

Costs of Invasive Meningococcal Disease: A Global Systematic Review

Abstract: Invasive meningococcal disease can result in substantial costs to healthcare systems. However, costing data on long-term follow-up and indirect costs used to populate health economic models are lacking.

Cited by 24 publications

References 60 publications

Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database

Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database

Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol

Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database

Contact Info

Product

Resources

About